PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2020 RESULTS AND RELEASES 5-YEAR PIPELINE METRICS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Pfizer (PFE) Misses Q4 EPS by 6c, Raises FY21 EPS Guidance
February 2, 2021 6:47 AM ESTPfizer (NYSE: PFE) reported Q4 EPS of $0.42, $0.06 worse than the analyst estimate of $0.48. Revenue for the quarter came in at $11.7 billion versus the consensus estimate of $11.43 billion.
GUIDANCE:
Pfizer sees FY2021 EPS of $3.10-$3.20, versus the consensus of $3.19. Pfizer sees... More
